The global Peptide Biosimilar market was valued at approximately USD 7.1 billion in 2023 and is forecast to reach USD 18.6 billion by 2032, expanding at a CAGR of 11.4% during the forecast period. Rising biologic drug demand, increasing chronic disease prevalence, and patent expirations of branded peptide therapeutics are significantly accelerating market growth. More than 537 million adults globally were diagnosed with diabetes in 2023, creating substantial demand for peptide-based biosimilar therapies.
Topics
